Article(id=1330225632803401740, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1330225632362999820, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2022.06.001, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1638288000000, receivedDateStr=2021-12-01, revisedDate=1649692800000, revisedDateStr=2022-04-12, acceptedDate=null, acceptedDateStr=null, onlineDate=1795080105256, onlineDateStr=2026-11-19, pubDate=1654790400000, pubDateStr=2022-06-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1795080105256, onlineIssueDateStr=2026-11-19, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1795080105256, creator=13701087609, updateTime=1795080105256, updator=13701087609, issue=Issue{id=1330225632362999820, tenantId=1146029695717560320, journalId=1319690329412173987, year='2022', volume='43', issue='6', pageStart='643', pageEnd='810', issueExtLink='null', onlineDate='null', pubDate='1654790400000', pubDateStr='2022-06-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1795080105152, creator='13701087609', updateTime=1795084738205, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1330245065345184449, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1330225632362999820, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1330245065345184450, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1330225632362999820, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=643, endPage=650, ext={EN=ArticleExt(id=1330225632992145421, articleId=1330225632803401740, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Research progress on sodium-glucose linked transporter 2 inhibitors in the treatment of heart failure, columnId=1325221107665612978, journalTitle=World Clinical Drug, columnName=Topic, runingTitle=null, highlight=null, articleAbstract=

Patients with heart failure (HF) have a higher risk of death, and diabetes mellitus (DM) is an important risk factor for HF. Sodium-glucose linked transporter 2 (SGLT2) inhibitor, as a new anti-hyperglycemia drug in recent years, has been proved to prevent cardiovascular events and improve the prognosis of patients with HF with reduced ejection fraction (HFrEF), and reduce the risk of HF hospitalization and cardiovascular death. This benefit is consistent in patients with or without DM. This article reviewed the previous literature on the effects of SGLT2 inhibitors on cardiovascular outcomes, especially on HF, in order to provide references for clinical medication.

, authors=Yue MING1, Nianxi YU2, Xingyun HOU2, Xia TAO2, *, authorsList=Yue MING, Nianxi YU, Xingyun HOU, Xia TAO, authorCompany=null, correspAuthors=Xia TAO, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1330225633252192270, articleId=1330225632803401740, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=钠-葡萄糖耦联转运体2抑制剂治疗心力衰竭的研究进展, columnId=1325221107824996532, journalTitle=世界临床药物, columnName=医药专论, runingTitle=null, highlight=null, articleAbstract=

心力衰竭(heart failure,HF)患者死亡风险较高,而糖尿病(diabetes mellitus,DM)是HF的重要危险因素。钠-葡萄糖耦联转运体2(sodium-glucose linked transporter 2,SGLT2)抑制剂作为近年来的一种新型抗高血糖药,已被证实可预防心血管事件,改善射血分数下降的HF(heart failure with reduced ejection fraction,HFrEF)患者预后,降低HF住院风险及心血管死亡风险,且这种获益在伴或不伴DM患者中是一致的。现就SGLT2抑制剂对心血管结局,尤其是影响HF的相关既往文献进行综述,旨在为临床用药提供参考。

, authors=明月1, 余年喜2, 侯幸赟2, 陶霞2, *, authorsList=明月, 余年喜, 侯幸赟, 陶霞, authorCompany=null, correspAuthors=陶霞, authorNote=

# 对本文贡献等同

明月,硕士,主管药师,研究方向:临床药学与合理用药。

余年喜,硕士,主管药师,研究方向:临床药学与心血管合理用药。

, correspAuthorsNote=
陶霞,教授,博士,主任药师,研究方向:临床药学与心血管药理学。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=sPiGdIWlkxicGr4J3WmCGw==, magXml=svoQYluaaNHscMK1MNBgkA==, pdfUrl=null, pdf=oZtOTmQmm1+Ue5M6vXXASA==, pdfFileSize=1828019, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=uVACDbYe5SRkBZx/Jtq+0g==, mapNumber=null, fund=null)}, authors=[Author(id=1330225633621291030, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330225633721954328, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, authorId=1330225633621291030, language=EN, stringName=Yue MING, firstName=Yue, middleName=null, lastName=MING, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Department of Pharmacy, Army Medical Center of Chinese People's Liberation Army, Chongqing 400042, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225633805840409, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, authorId=1330225633621291030, language=CN, stringName=明月, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.陆军特色医学中心药剂科,重庆 400042, bio={"content":"

明月,硕士,主管药师,研究方向:临床药学与合理用药。

"}, bioImg=null, bioContent=

明月,硕士,主管药师,研究方向:临床药学与合理用药。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225633466101775, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, xref=1., ext=[AuthorCompanyExt(id=1330225633470296080, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, companyId=1330225633466101775, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Pharmacy, Army Medical Center of Chinese People's Liberation Army, Chongqing 400042, China), AuthorCompanyExt(id=1330225633478684689, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, companyId=1330225633466101775, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.陆军特色医学中心药剂科,重庆 400042)])]), Author(id=1330225633860366363, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330225633927475230, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, authorId=1330225633860366363, language=EN, stringName=Nianxi YU, firstName=Nianxi, middleName=null, lastName=YU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Department of Pharmacy, Second Affiliated Hospital of Naval Medical University, Shanghai 200433, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225634007167007, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, authorId=1330225633860366363, language=CN, stringName=余年喜, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.海军军医大学第二附属医院药剂科,上海 200433, bio={"content":"

余年喜,硕士,主管药师,研究方向:临床药学与心血管合理用药。

"}, bioImg=null, bioContent=

余年喜,硕士,主管药师,研究方向:临床药学与心血管合理用药。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225633541599250, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, xref=2., ext=[AuthorCompanyExt(id=1330225633554182163, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, companyId=1330225633541599250, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Pharmacy, Second Affiliated Hospital of Naval Medical University, Shanghai 200433, China), AuthorCompanyExt(id=1330225633562570772, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, companyId=1330225633541599250, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.海军军医大学第二附属医院药剂科,上海 200433)])]), Author(id=1330225634116218913, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330225634195910691, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, authorId=1330225634116218913, language=EN, stringName=Xingyun HOU, firstName=Xingyun, middleName=null, lastName=HOU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Department of Pharmacy, Second Affiliated Hospital of Naval Medical University, Shanghai 200433, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225634292379684, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, authorId=1330225634116218913, language=CN, stringName=侯幸赟, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.海军军医大学第二附属医院药剂科,上海 200433, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225633541599250, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, xref=2., ext=[AuthorCompanyExt(id=1330225633554182163, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, companyId=1330225633541599250, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Pharmacy, Second Affiliated Hospital of Naval Medical University, Shanghai 200433, China), AuthorCompanyExt(id=1330225633562570772, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, companyId=1330225633541599250, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.海军军医大学第二附属医院药剂科,上海 200433)])]), Author(id=1330225634359488550, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1330225634430791720, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, authorId=1330225634359488550, language=EN, stringName=Xia TAO, firstName=Xia, middleName=null, lastName=TAO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.Department of Pharmacy, Second Affiliated Hospital of Naval Medical University, Shanghai 200433, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225634485317673, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, authorId=1330225634359488550, language=CN, stringName=陶霞, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.海军军医大学第二附属医院药剂科,上海 200433, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225633541599250, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, xref=2., ext=[AuthorCompanyExt(id=1330225633554182163, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, companyId=1330225633541599250, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Pharmacy, Second Affiliated Hospital of Naval Medical University, Shanghai 200433, China), AuthorCompanyExt(id=1330225633562570772, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, companyId=1330225633541599250, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.海军军医大学第二附属医院药剂科,上海 200433)])])], keywords=[Keyword(id=1330225636125290540, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, language=EN, orderNo=1, keyword=sodium-glucose linked transporter 2 inhibitor), Keyword(id=1330225636192399405, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, language=EN, orderNo=2, keyword=heart failure), Keyword(id=1330225636259508270, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, language=EN, orderNo=3, keyword=diabetes mellitus), Keyword(id=1330225636326617135, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, language=EN, orderNo=4, keyword=cardiovascular outcome), Keyword(id=1330225636418891824, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, language=CN, orderNo=1, keyword=钠-葡萄糖耦联转运体2抑制剂), Keyword(id=1330225636481806385, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, language=CN, orderNo=2, keyword=心力衰竭), Keyword(id=1330225636557303858, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, language=CN, orderNo=3, keyword=糖尿病), Keyword(id=1330225636636995637, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, language=CN, orderNo=4, keyword=心血管结局)], refs=[Reference(id=1330225636859293751, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=Hao G, Wang X, Chen Z, et al. Prevalence of heart failure and left ventricular dysfunction in China: the China hypertension survey, 2012-2015[J]. Eur J Heart Fail, 2019, 21(11): 1329-1337., articleTitle=null, refAbstract=null), Reference(id=1330225636922208312, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=Murphy SP, Ibrahim NE, Januzzi JL Jr. Heart failure with reduced ejection fraction: a review[J]. JAMA, 2020, 324(5): 488-504., articleTitle=null, refAbstract=null), Reference(id=1330225636972539961, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=Echouffo-Tcheugui JB, Xu H, Devore AD, et al. Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: findings from get with the guidelines-heart failure registry[J]. Am Heart J, 2016, 182: 9-20., articleTitle=null, refAbstract=null), Reference(id=1330225637052231738, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=Verma S, Mcmurray JJV. The serendipitous story of SGLT2 inhibitors in heart failure[J]. Circulation, 2019, 139(22): 2537-2541., articleTitle=null, refAbstract=null), Reference(id=1330225637119340603, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=Mcallister DA, Read SH, Kerssens J, et al. Incidence of hospitalization for heart failure and case-fatality among 3.25 million people with and without diabetes mellitus[J]. Circulation, 2018, 138(24): 2774-2786., articleTitle=null, refAbstract=null), Reference(id=1330225637186449468, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=Dunlay SM, Givertz MM, Aguilar D, et al. Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update[J]. Circulation, 2019, 140(7): e294-e324., articleTitle=null, refAbstract=null), Reference(id=1330225637249364029, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=Zareini B, Blanche P, D'souza M, et al. Type 2 diabetes mellitus and impact of heart failure on prognosis compared to other cardiovascular diseases: a nationwide study[J]. Circ Cardiovasc Qual Outcomes, 2020, 13(7): e006260., articleTitle=null, refAbstract=null), Reference(id=1330225637312278590, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes[J]. N Engl J Med, 2015, 373(22): 2117-2128., articleTitle=null, refAbstract=null), Reference(id=1330225637400358975, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=Kosiborod M, Cavender MA, Fu AZ, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors)[J]. Circulation, 2017, 136(3): 249-259., articleTitle=null, refAbstract=null), Reference(id=1330225637475856448, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes[J]. N Engl J Med, 2017, 377(7): 644-657., articleTitle=null, refAbstract=null), Reference(id=1330225637542965313, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=Mcmurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction[J]. N Engl J Med, 2019, 381(21): 1995-2008., articleTitle=null, refAbstract=null), Reference(id=1330225637610074178, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=Anker SD, Butler J, Filippatos G, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure[J]. N Engl J Med, 2020, 383(15): 1413-1424., articleTitle=null, refAbstract=null), Reference(id=1330225637685571651, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study[J]. Lancet, 2010, 376(9744): 875-885., articleTitle=null, refAbstract=null), Reference(id=1330225637756874821, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=Mcmurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure[J]. N Engl J Med, 2014, 371(11): 993-1004., articleTitle=null, refAbstract=null), Reference(id=1330225637819789382, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control[J]. Nat Rev Cardiol, 2020, 17(12): 761-772., articleTitle=null, refAbstract=null), Reference(id=1330225637899481159, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=Zelniker TA, Braunwald E. Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review[J]. J Am Coll Cardiol, 2020, 75(4): 422-434., articleTitle=null, refAbstract=null), Reference(id=1330225637962395720, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=Marton A, Kaneko T, Kovalik JP, et al. Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation[J]. Nat Rev Nephrol, 2021, 17(1): 65-77., articleTitle=null, refAbstract=null), Reference(id=1330225638037893193, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review[J]. JACC Basic Transl Sci, 2020, 5(6): 632-644., articleTitle=null, refAbstract=null), Reference(id=1330225638109196364, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=Zinman B, Inzucchi SE, Lachin JM, et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOMETM)[J]. Cardiovasc Diabetol, 2014, 13: 102., articleTitle=null, refAbstract=null), Reference(id=1330225638180499533, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=Mcguire DK, Zinman B, Inzucchi SE, et al. Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial[J]. Lancet Diabetes Endocrinol, 2020, 8(12): 949-959., articleTitle=null, refAbstract=null), Reference(id=1330225638260191310, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial[J]. Eur Heart J, 2016, 37(19): 1526-1534., articleTitle=null, refAbstract=null), Reference(id=1330225638323105871, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=Fitchett D, Inzucchi SE, Lachin JM, et al. Cardiovascular mortality reduction with empagliflozin in patients with type 2 diabetes and cardiovascular disease[J]. J Am Coll Cardiol, 2018, 71(3): 364-367., articleTitle=null, refAbstract=null), Reference(id=1330225638390214736, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=Verma S, Mazer CD, Bhatt DL, et al. Empagliflozin and cardiovascular outcomes in patients with type 2 diabetes and left ventricular hypertrophy: a subanalysis of the EMPA-REG OUTCOME trial[J]. Diabetes Care, 2019, 42(3): e42-e44., articleTitle=null, refAbstract=null), Reference(id=1330225638453129297, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=Fitchett D, Inzucchi SE, Cannon CP, et al. Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial[J]. Circulation, 2019, 139(11): 1384-1395., articleTitle=null, refAbstract=null), Reference(id=1330225638524432466, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=Mahaffey KW, Neal B, Perkovic V, et al. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study)[J]. Circulation, 2018, 137(4): 323-334., articleTitle=null, refAbstract=null), Reference(id=1330225638629290067, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy[J]. N Engl J Med, 2019, 380(24): 2295-2306., articleTitle=null, refAbstract=null), Reference(id=1330225638708981844, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=Wiviott SD, Raz I, Bonaca MP, et al. The design and rationale for the dapagliflozin effect on cardiovascular events (DECLARE)-TIMI 58 trial[J]. Am Heart J, 2018, 200: 83-89., articleTitle=null, refAbstract=null), Reference(id=1330225638767702101, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med, 2019, 380(4): 347-357., articleTitle=null, refAbstract=null), Reference(id=1330225638834810966, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=Furtado RHM, Bonaca MP, Raz I, et al. Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction[J]. Circulation, 2019, 139(22): 2516-2527., articleTitle=null, refAbstract=null), Reference(id=1330225638901919831, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=Bonaca MP, Wiviott SD, Zelniker TA, et al. Dapagliflozin and cardiac, kidney, and limb outcomes in patients with and without peripheral artery disease in DECLARE-TIMI 58[J]. Circulation, 2020, 142(8): 734-747., articleTitle=null, refAbstract=null), Reference(id=1330225638969028698, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=Zelniker TA, Morrow DA, Mosenzon O, et al. Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58[J]. Eur J Heart Fail, 2021, 23(6): 1026-1036., articleTitle=null, refAbstract=null), Reference(id=1330225640609001563, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=Cahn A, Mosenzon O, Wiviott SD, et al. Efficacy and safety of dapagliflozin in the elderly: analysis from the DECLARE-TIMI 58 study[J]. Diabetes Care, 2020, 43(2): 468-475., articleTitle=null, refAbstract=null), Reference(id=1330225640680304732, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=Zelniker TA, Bonaca MP, Furtado RHM, et al. Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE-TIMI 58 trial[J]. Circulation, 2020, 141(15): 1227-1234., articleTitle=null, refAbstract=null), Reference(id=1330225640743219293, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=Kato ET, Silverman MG, Mosenzon O, et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus[J]. Circulation, 2019, 139(22): 2528-2536., articleTitle=null, refAbstract=null), Reference(id=1330225640827105374, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes[J]. N Engl J Med, 2020, 383(15): 1425-1435., articleTitle=null, refAbstract=null), Reference(id=1330225640898408543, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=Cosentino F, Cannon CP, Cherney DZI, et al. Efficacy of ertugliflozin on heart failure-related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: results of the VERTIS CV trial[J]. Circulation, 2020, 142(23): 2205-2215., articleTitle=null, refAbstract=null), Reference(id=1330225640982294624, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure[J]. N Engl J Med, 2021, 384(2): 117-128., articleTitle=null, refAbstract=null), Reference(id=1330225641066180705, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=Docherty KF, Mcmurray JJV. SOLOIST-WHF and updated meta-analysis: sodium-glucose co-transporter 2 inhibitors should be initiated in patients hospitalized with worsening heart failure[J]. Eur J Heart Fail, 2021, 23(1): 27-30., articleTitle=null, refAbstract=null), Reference(id=1330225641129095266, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[39], rfOrder=38, authorNames=null, journalName=null, refType=null, unstructuredReference=Nassif ME, Windsor SL, Tang F, et al. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial[J]. Circulation, 2019, 140(18): 1463-1476., articleTitle=null, refAbstract=null), Reference(id=1330225641196204131, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[40], rfOrder=39, authorNames=null, journalName=null, refType=null, unstructuredReference=Mcmurray JJV, Demets DL, Inzucchi SE, et al. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)[J]. Eur J Heart Fail, 2019, 21(5): 665-675., articleTitle=null, refAbstract=null), Reference(id=1330225641263312996, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[41], rfOrder=40, authorNames=null, journalName=null, refType=null, unstructuredReference=Petrie MC, Verma S, Docherty KF, et al. Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes[J]. JAMA, 2020, 323(14): 1353-1368., articleTitle=null, refAbstract=null), Reference(id=1330225641338810469, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[42], rfOrder=41, authorNames=null, journalName=null, refType=null, unstructuredReference=Packer M, Butler J, Filippatos GS, et al. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-reduced trial[J]. Eur J Heart Fail, 2019, 21(10): 1270-1278., articleTitle=null, refAbstract=null), Reference(id=1330225641397530726, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[43], rfOrder=42, authorNames=null, journalName=null, refType=null, unstructuredReference=Anker SD, Butler J, Filippatos G, et al. Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: results from the EMPEROR-reduced trial[J]. Circulation, 2021, 143(4): 337-349., articleTitle=null, refAbstract=null), Reference(id=1330225641468833895, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[44], rfOrder=43, authorNames=null, journalName=null, refType=null, unstructuredReference=Packer M, Januzzi JL, Ferreira JP, et al. Concentration-dependent clinical and prognostic importance of high-sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR-reduced trial[J]. Eur J Heart Fail, 2021, 23(9): 1529-1538., articleTitle=null, refAbstract=null), Reference(id=1330225641548525672, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[45], rfOrder=44, authorNames=null, journalName=null, refType=null, unstructuredReference=Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-reduced and DAPA-HF trials[J]. Lancet, 2020, 396(10254): 819-829., articleTitle=null, refAbstract=null), Reference(id=1330225641611440233, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[46], rfOrder=45, authorNames=null, journalName=null, refType=null, unstructuredReference=Jarcho JA. More evidence for SGLT2 inhibitors in heart failure[J]. N Engl J Med, 2020, 383(15): 1481-1482., articleTitle=null, refAbstract=null), Reference(id=1330225641682743402, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[47], rfOrder=46, authorNames=null, journalName=null, refType=null, unstructuredReference=Docherty KF, Jhund PS, Inzucchi SE, et al. Effects of dapagliflozin in DAPA-HF according to background heart failure therapy[J]. Eur Heart J, 2020, 41(25): 2379-2392., articleTitle=null, refAbstract=null), Reference(id=1330225641749852267, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[48], rfOrder=47, authorNames=null, journalName=null, refType=null, unstructuredReference=Packer M, Anker SD, Butler J, et al. Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-reduced trial[J]. Eur Heart J, 2021, 42(6): 671-680., articleTitle=null, refAbstract=null), Reference(id=1330225641825349740, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[49], rfOrder=48, authorNames=null, journalName=null, refType=null, unstructuredReference=Ferreira JP, Zannad F, Pocock SJ, et al. Interplay of mineralocorticoid receptor antagonists and empagliflozin in heart failure: EMPEROR-reduced[J]. J Am Coll Cardiol, 2021, 77(11): 1397-1407., articleTitle=null, refAbstract=null), Reference(id=1330225641905041517, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[50], rfOrder=49, authorNames=null, journalName=null, refType=null, unstructuredReference=Vaduganathan M, Claggett BL, Jhund PS, et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials[J]. Lancet, 2020, 396(10244): 121-128., articleTitle=null, refAbstract=null), Reference(id=1330225641976344686, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[51], rfOrder=50, authorNames=null, journalName=null, refType=null, unstructuredReference=Rossignol P, Hernandez AF, Solomon SD, et al. Heart failure drug treatment[J]. Lancet, 2019, 393(10175): 1034-1044., articleTitle=null, refAbstract=null), Reference(id=1330225642043453551, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[52], rfOrder=51, authorNames=null, journalName=null, refType=null, unstructuredReference=Pabel S, Hamdani N, Sossalla S. A mechanistic rationale for the investigation of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction. Letter regarding the article 'Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-preserved trial'[J]. Eur J Heart Fail, 2021, 23(5): 841., articleTitle=null, refAbstract=null), Reference(id=1330225642102173808, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[53], rfOrder=52, authorNames=null, journalName=null, refType=null, unstructuredReference=Williams DM, Evans M. Dapagliflozin for heart failure with preserved ejection fraction: will the DELIVER study deliver?[J]. Diabetes Ther, 2020, 11(10): 2207-2219., articleTitle=null, refAbstract=null), Reference(id=1330225642165088369, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[54], rfOrder=53, authorNames=null, journalName=null, refType=null, unstructuredReference=Donnan JR, Grandy CA, Chibrikov E, et al. Dose response of sodium glucose cotransporter-2 inhibitors in relation to urinary tract infections: a systematic review and network meta-analysis of randomized controlled trials[J]. CMAJ Open, 2018, 6(4): e594-e602., articleTitle=null, refAbstract=null), Reference(id=1330225642228002930, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[55], rfOrder=54, authorNames=null, journalName=null, refType=null, unstructuredReference=Mcgill JB, Subramanian S. Safety of sodium-glucose co-transporter 2 inhibitors[J]. Am J Cardiol, 2019, 124(Suppl 1): S45-S52., articleTitle=null, refAbstract=null), Reference(id=1330225642282528883, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[56], rfOrder=55, authorNames=null, journalName=null, refType=null, unstructuredReference=Vardeny O. The sweet spot: heart failure prevention with SGLT2 inhibitors[J]. Am J Med, 2020, 133(2): 182-185., articleTitle=null, refAbstract=null), Reference(id=1330225642370609268, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[57], rfOrder=56, authorNames=null, journalName=null, refType=null, unstructuredReference=Hu Y, Bai Z, Tang Y, et al. Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a pharmacovigilance study with data from the U. S. FDA Adverse Event Reporting System[J]. J Diabetes Res, 2020, 2020: 3695101., articleTitle=null, refAbstract=null), Reference(id=1330225642450301045, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[58], rfOrder=57, authorNames=null, journalName=null, refType=null, unstructuredReference=Handelsman Y, Henry RR, Bloomgarden ZT, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis[J]. Endocr Pract, 2016, 22(6): 753-762., articleTitle=null, refAbstract=null), Reference(id=1330225642513215606, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[59], rfOrder=58, authorNames=null, journalName=null, refType=null, unstructuredReference=Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD[J]. Eur Heart J, 2020, 41(2): 255-323., articleTitle=null, refAbstract=null), Reference(id=1330225642580324471, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[60], rfOrder=59, authorNames=null, journalName=null, refType=null, unstructuredReference=American Diabetes Association. Cardiovascular disease and risk management: standards of medical care in diabetes-2021[J]. Diabetes Care, 2021, 44(Suppl 1): S125-S150., articleTitle=null, refAbstract=null), Reference(id=1330225642664210552, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[61], rfOrder=60, authorNames=null, journalName=null, refType=null, unstructuredReference=Gao Y, Peterson E, Pagidipati N. Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits[J]. Am Heart J, 2020, 224: 47-53., articleTitle=null, refAbstract=null), Reference(id=1330225642722930809, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[62], rfOrder=61, authorNames=null, journalName=null, refType=null, unstructuredReference=Hamid A, Vaduganathan M, Oshunbade AA, et al. Antihyperglycemic therapies with expansions of US Food and Drug Administration Indications to reduce cardiovascular events: prescribing patterns within an academic medical center[J]. J Cardiovasc Pharmacol, 2020, 76(3): 313-320., articleTitle=null, refAbstract=null), Reference(id=1330225642785845370, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[63], rfOrder=62, authorNames=null, journalName=null, refType=null, unstructuredReference=O'meara E, Mcdonald M, Chan M, et al. CCS/CHFS Heart Failure Guidelines: clinical trial update on functional mitral regurgitation, SGLT2 inhibitors, arni in HFpEF, and tafamidis in amyloidosis[J]. Can J Cardiol, 2020, 36(2): 159-169., articleTitle=null, refAbstract=null), Reference(id=1330225642848759931, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[64], rfOrder=63, authorNames=null, journalName=null, refType=null, unstructuredReference=Maddox TM, Januzzi JL Jr, Allen LA, et al. 2021 Update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American college of cardiology solution set oversight committee[J]. J Am Coll Cardiol, 2021, 77(6): 772-810., articleTitle=null, refAbstract=null)], funds=[Fund(id=1330225636767019062, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, awardId=null, language=CN, fundingSource=上海市“医苑新星”青年医学人才培养资助计划(青年医学人才类——临床药师项目), fundOrder=null, country=null)], companyList=[AuthorCompany(id=1330225633466101775, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, xref=1., ext=[AuthorCompanyExt(id=1330225633470296080, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, companyId=1330225633466101775, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Pharmacy, Army Medical Center of Chinese People's Liberation Army, Chongqing 400042, China), AuthorCompanyExt(id=1330225633478684689, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, companyId=1330225633466101775, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.陆军特色医学中心药剂科,重庆 400042)]), AuthorCompany(id=1330225633541599250, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, xref=2., ext=[AuthorCompanyExt(id=1330225633554182163, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, companyId=1330225633541599250, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Pharmacy, Second Affiliated Hospital of Naval Medical University, Shanghai 200433, China), AuthorCompanyExt(id=1330225633562570772, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, companyId=1330225633541599250, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.海军军医大学第二附属医院药剂科,上海 200433)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2022.06.001, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2022.06.001, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2022.06.001, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2022.06.001, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1654790400000, fullTextJson=null, articleText=null, reference=null)
收藏切换
钠-葡萄糖耦联转运体2抑制剂治疗心力衰竭的研究进展
明月 1 , 余年喜 2 , 侯幸赟 2 , 陶霞 2, *
世界临床药物 | 医药专论 2022,43(6): 643-650
收起
收藏切换
世界临床药物 |医药专论 2022 , 43 (6) : 643 -650
钠-葡萄糖耦联转运体2抑制剂治疗心力衰竭的研究进展
全屏
[Author(id=1330225633621291030, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330225633721954328, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, authorId=1330225633621291030, language=EN, stringName=Yue MING, firstName=Yue, middleName=null, lastName=MING, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Department of Pharmacy, Army Medical Center of Chinese People's Liberation Army, Chongqing 400042, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225633805840409, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, authorId=1330225633621291030, language=CN, stringName=明月, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.陆军特色医学中心药剂科,重庆 400042, bio={"content":"

明月,硕士,主管药师,研究方向:临床药学与合理用药。

"}, bioImg=null, bioContent=

明月,硕士,主管药师,研究方向:临床药学与合理用药。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225633466101775, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, xref=1., ext=[AuthorCompanyExt(id=1330225633470296080, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, companyId=1330225633466101775, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Pharmacy, Army Medical Center of Chinese People's Liberation Army, Chongqing 400042, China), AuthorCompanyExt(id=1330225633478684689, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, companyId=1330225633466101775, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.陆军特色医学中心药剂科,重庆 400042)])]), Author(id=1330225633860366363, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330225633927475230, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, authorId=1330225633860366363, language=EN, stringName=Nianxi YU, firstName=Nianxi, middleName=null, lastName=YU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Department of Pharmacy, Second Affiliated Hospital of Naval Medical University, Shanghai 200433, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225634007167007, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, authorId=1330225633860366363, language=CN, stringName=余年喜, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.海军军医大学第二附属医院药剂科,上海 200433, bio={"content":"

余年喜,硕士,主管药师,研究方向:临床药学与心血管合理用药。

"}, bioImg=null, bioContent=

余年喜,硕士,主管药师,研究方向:临床药学与心血管合理用药。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225633541599250, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, xref=2., ext=[AuthorCompanyExt(id=1330225633554182163, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, companyId=1330225633541599250, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Pharmacy, Second Affiliated Hospital of Naval Medical University, Shanghai 200433, China), AuthorCompanyExt(id=1330225633562570772, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, companyId=1330225633541599250, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.海军军医大学第二附属医院药剂科,上海 200433)])]), Author(id=1330225634116218913, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330225634195910691, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, authorId=1330225634116218913, language=EN, stringName=Xingyun HOU, firstName=Xingyun, middleName=null, lastName=HOU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Department of Pharmacy, Second Affiliated Hospital of Naval Medical University, Shanghai 200433, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225634292379684, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, authorId=1330225634116218913, language=CN, stringName=侯幸赟, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.海军军医大学第二附属医院药剂科,上海 200433, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225633541599250, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, xref=2., ext=[AuthorCompanyExt(id=1330225633554182163, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, companyId=1330225633541599250, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Pharmacy, Second Affiliated Hospital of Naval Medical University, Shanghai 200433, China), AuthorCompanyExt(id=1330225633562570772, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, companyId=1330225633541599250, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.海军军医大学第二附属医院药剂科,上海 200433)])]), Author(id=1330225634359488550, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1330225634430791720, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, authorId=1330225634359488550, language=EN, stringName=Xia TAO, firstName=Xia, middleName=null, lastName=TAO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.Department of Pharmacy, Second Affiliated Hospital of Naval Medical University, Shanghai 200433, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225634485317673, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, authorId=1330225634359488550, language=CN, stringName=陶霞, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.海军军医大学第二附属医院药剂科,上海 200433, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225633541599250, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, xref=2., ext=[AuthorCompanyExt(id=1330225633554182163, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, companyId=1330225633541599250, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Pharmacy, Second Affiliated Hospital of Naval Medical University, Shanghai 200433, China), AuthorCompanyExt(id=1330225633562570772, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225632803401740, companyId=1330225633541599250, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.海军军医大学第二附属医院药剂科,上海 200433)])])]
明月1, 余年喜2, 侯幸赟2, 陶霞2, *
作者信息
  • 1.陆军特色医学中心药剂科,重庆 400042
  • 2.海军军医大学第二附属医院药剂科,上海 200433
通讯作者:
陶霞,教授,博士,主任药师,研究方向:临床药学与心血管药理学。
作者简介:

# 对本文贡献等同

明月,硕士,主管药师,研究方向:临床药学与合理用药。

余年喜,硕士,主管药师,研究方向:临床药学与心血管合理用药。

Research progress on sodium-glucose linked transporter 2 inhibitors in the treatment of heart failure
Yue MING1, Nianxi YU2, Xingyun HOU2, Xia TAO2, *
Affiliations
  • 1.Department of Pharmacy, Army Medical Center of Chinese People's Liberation Army, Chongqing 400042, China
  • 2.Department of Pharmacy, Second Affiliated Hospital of Naval Medical University, Shanghai 200433, China
出版时间: 2022-06-10 doi: 10.13683/j.wph.2022.06.001
文章导航
收藏切换

心力衰竭(heart failure,HF)患者死亡风险较高,而糖尿病(diabetes mellitus,DM)是HF的重要危险因素。钠-葡萄糖耦联转运体2(sodium-glucose linked transporter 2,SGLT2)抑制剂作为近年来的一种新型抗高血糖药,已被证实可预防心血管事件,改善射血分数下降的HF(heart failure with reduced ejection fraction,HFrEF)患者预后,降低HF住院风险及心血管死亡风险,且这种获益在伴或不伴DM患者中是一致的。现就SGLT2抑制剂对心血管结局,尤其是影响HF的相关既往文献进行综述,旨在为临床用药提供参考。

钠-葡萄糖耦联转运体2抑制剂  /  心力衰竭  /  糖尿病  /  心血管结局

Patients with heart failure (HF) have a higher risk of death, and diabetes mellitus (DM) is an important risk factor for HF. Sodium-glucose linked transporter 2 (SGLT2) inhibitor, as a new anti-hyperglycemia drug in recent years, has been proved to prevent cardiovascular events and improve the prognosis of patients with HF with reduced ejection fraction (HFrEF), and reduce the risk of HF hospitalization and cardiovascular death. This benefit is consistent in patients with or without DM. This article reviewed the previous literature on the effects of SGLT2 inhibitors on cardiovascular outcomes, especially on HF, in order to provide references for clinical medication.

sodium-glucose linked transporter 2 inhibitor  /  heart failure  /  diabetes mellitus  /  cardiovascular outcome
明月, 余年喜, 侯幸赟, 陶霞. 钠-葡萄糖耦联转运体2抑制剂治疗心力衰竭的研究进展. 世界临床药物, 2022 , 43 (6) : 643 -650 . DOI: 10.13683/j.wph.2022.06.001
Yue MING, Nianxi YU, Xingyun HOU, Xia TAO. Research progress on sodium-glucose linked transporter 2 inhibitors in the treatment of heart failure[J]. World Clinical Drug, 2022 , 43 (6) : 643 -650 . DOI: 10.13683/j.wph.2022.06.001
  • 上海市“医苑新星”青年医学人才培养资助计划(青年医学人才类——临床药师项目)
参考文献 引证文献
排序方式:
[1]
Hao G, Wang X, Chen Z, et al. Prevalence of heart failure and left ventricular dysfunction in China: the China hypertension survey, 2012-2015[J]. Eur J Heart Fail, 2019, 21(11): 1329-1337.
[2]
Murphy SP, Ibrahim NE, Januzzi JL Jr. Heart failure with reduced ejection fraction: a review[J]. JAMA, 2020, 324(5): 488-504.
[3]
Echouffo-Tcheugui JB, Xu H, Devore AD, et al. Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: findings from get with the guidelines-heart failure registry[J]. Am Heart J, 2016, 182: 9-20.
[4]
Verma S, Mcmurray JJV. The serendipitous story of SGLT2 inhibitors in heart failure[J]. Circulation, 2019, 139(22): 2537-2541.
[5]
Mcallister DA, Read SH, Kerssens J, et al. Incidence of hospitalization for heart failure and case-fatality among 3.25 million people with and without diabetes mellitus[J]. Circulation, 2018, 138(24): 2774-2786.
[6]
Dunlay SM, Givertz MM, Aguilar D, et al. Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update[J]. Circulation, 2019, 140(7): e294-e324.
[7]
Zareini B, Blanche P, D'souza M, et al. Type 2 diabetes mellitus and impact of heart failure on prognosis compared to other cardiovascular diseases: a nationwide study[J]. Circ Cardiovasc Qual Outcomes, 2020, 13(7): e006260.
[8]
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes[J]. N Engl J Med, 2015, 373(22): 2117-2128.
[9]
Kosiborod M, Cavender MA, Fu AZ, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors)[J]. Circulation, 2017, 136(3): 249-259.
[10]
Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes[J]. N Engl J Med, 2017, 377(7): 644-657.
[11]
Mcmurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction[J]. N Engl J Med, 2019, 381(21): 1995-2008.
[12]
Anker SD, Butler J, Filippatos G, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure[J]. N Engl J Med, 2020, 383(15): 1413-1424.
[13]
Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study[J]. Lancet, 2010, 376(9744): 875-885.
[14]
Mcmurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure[J]. N Engl J Med, 2014, 371(11): 993-1004.
[15]
Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control[J]. Nat Rev Cardiol, 2020, 17(12): 761-772.
[16]
Zelniker TA, Braunwald E. Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review[J]. J Am Coll Cardiol, 2020, 75(4): 422-434.
[17]
Marton A, Kaneko T, Kovalik JP, et al. Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation[J]. Nat Rev Nephrol, 2021, 17(1): 65-77.
[18]
Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review[J]. JACC Basic Transl Sci, 2020, 5(6): 632-644.
[19]
Zinman B, Inzucchi SE, Lachin JM, et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOMETM)[J]. Cardiovasc Diabetol, 2014, 13: 102.
[20]
Mcguire DK, Zinman B, Inzucchi SE, et al. Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial[J]. Lancet Diabetes Endocrinol, 2020, 8(12): 949-959.
[21]
Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial[J]. Eur Heart J, 2016, 37(19): 1526-1534.
[22]
Fitchett D, Inzucchi SE, Lachin JM, et al. Cardiovascular mortality reduction with empagliflozin in patients with type 2 diabetes and cardiovascular disease[J]. J Am Coll Cardiol, 2018, 71(3): 364-367.
[23]
Verma S, Mazer CD, Bhatt DL, et al. Empagliflozin and cardiovascular outcomes in patients with type 2 diabetes and left ventricular hypertrophy: a subanalysis of the EMPA-REG OUTCOME trial[J]. Diabetes Care, 2019, 42(3): e42-e44.
[24]
Fitchett D, Inzucchi SE, Cannon CP, et al. Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial[J]. Circulation, 2019, 139(11): 1384-1395.
[25]
Mahaffey KW, Neal B, Perkovic V, et al. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study)[J]. Circulation, 2018, 137(4): 323-334.
[26]
Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy[J]. N Engl J Med, 2019, 380(24): 2295-2306.
[27]
Wiviott SD, Raz I, Bonaca MP, et al. The design and rationale for the dapagliflozin effect on cardiovascular events (DECLARE)-TIMI 58 trial[J]. Am Heart J, 2018, 200: 83-89.
[28]
Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med, 2019, 380(4): 347-357.
[29]
Furtado RHM, Bonaca MP, Raz I, et al. Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction[J]. Circulation, 2019, 139(22): 2516-2527.
[30]
Bonaca MP, Wiviott SD, Zelniker TA, et al. Dapagliflozin and cardiac, kidney, and limb outcomes in patients with and without peripheral artery disease in DECLARE-TIMI 58[J]. Circulation, 2020, 142(8): 734-747.
[31]
Zelniker TA, Morrow DA, Mosenzon O, et al. Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58[J]. Eur J Heart Fail, 2021, 23(6): 1026-1036.
[32]
Cahn A, Mosenzon O, Wiviott SD, et al. Efficacy and safety of dapagliflozin in the elderly: analysis from the DECLARE-TIMI 58 study[J]. Diabetes Care, 2020, 43(2): 468-475.
[33]
Zelniker TA, Bonaca MP, Furtado RHM, et al. Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE-TIMI 58 trial[J]. Circulation, 2020, 141(15): 1227-1234.
[34]
Kato ET, Silverman MG, Mosenzon O, et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus[J]. Circulation, 2019, 139(22): 2528-2536.
[35]
Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes[J]. N Engl J Med, 2020, 383(15): 1425-1435.
[36]
Cosentino F, Cannon CP, Cherney DZI, et al. Efficacy of ertugliflozin on heart failure-related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: results of the VERTIS CV trial[J]. Circulation, 2020, 142(23): 2205-2215.
[37]
Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure[J]. N Engl J Med, 2021, 384(2): 117-128.
[38]
Docherty KF, Mcmurray JJV. SOLOIST-WHF and updated meta-analysis: sodium-glucose co-transporter 2 inhibitors should be initiated in patients hospitalized with worsening heart failure[J]. Eur J Heart Fail, 2021, 23(1): 27-30.
[39]
Nassif ME, Windsor SL, Tang F, et al. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial[J]. Circulation, 2019, 140(18): 1463-1476.
[40]
Mcmurray JJV, Demets DL, Inzucchi SE, et al. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)[J]. Eur J Heart Fail, 2019, 21(5): 665-675.
[41]
Petrie MC, Verma S, Docherty KF, et al. Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes[J]. JAMA, 2020, 323(14): 1353-1368.
[42]
Packer M, Butler J, Filippatos GS, et al. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-reduced trial[J]. Eur J Heart Fail, 2019, 21(10): 1270-1278.
[43]
Anker SD, Butler J, Filippatos G, et al. Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: results from the EMPEROR-reduced trial[J]. Circulation, 2021, 143(4): 337-349.
[44]
Packer M, Januzzi JL, Ferreira JP, et al. Concentration-dependent clinical and prognostic importance of high-sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR-reduced trial[J]. Eur J Heart Fail, 2021, 23(9): 1529-1538.
[45]
Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-reduced and DAPA-HF trials[J]. Lancet, 2020, 396(10254): 819-829.
[46]
Jarcho JA. More evidence for SGLT2 inhibitors in heart failure[J]. N Engl J Med, 2020, 383(15): 1481-1482.
[47]
Docherty KF, Jhund PS, Inzucchi SE, et al. Effects of dapagliflozin in DAPA-HF according to background heart failure therapy[J]. Eur Heart J, 2020, 41(25): 2379-2392.
[48]
Packer M, Anker SD, Butler J, et al. Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-reduced trial[J]. Eur Heart J, 2021, 42(6): 671-680.
[49]
Ferreira JP, Zannad F, Pocock SJ, et al. Interplay of mineralocorticoid receptor antagonists and empagliflozin in heart failure: EMPEROR-reduced[J]. J Am Coll Cardiol, 2021, 77(11): 1397-1407.
[50]
Vaduganathan M, Claggett BL, Jhund PS, et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials[J]. Lancet, 2020, 396(10244): 121-128.
[51]
Rossignol P, Hernandez AF, Solomon SD, et al. Heart failure drug treatment[J]. Lancet, 2019, 393(10175): 1034-1044.
[52]
Pabel S, Hamdani N, Sossalla S. A mechanistic rationale for the investigation of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction. Letter regarding the article 'Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-preserved trial'[J]. Eur J Heart Fail, 2021, 23(5): 841.
[53]
Williams DM, Evans M. Dapagliflozin for heart failure with preserved ejection fraction: will the DELIVER study deliver?[J]. Diabetes Ther, 2020, 11(10): 2207-2219.
[54]
Donnan JR, Grandy CA, Chibrikov E, et al. Dose response of sodium glucose cotransporter-2 inhibitors in relation to urinary tract infections: a systematic review and network meta-analysis of randomized controlled trials[J]. CMAJ Open, 2018, 6(4): e594-e602.
[55]
Mcgill JB, Subramanian S. Safety of sodium-glucose co-transporter 2 inhibitors[J]. Am J Cardiol, 2019, 124(Suppl 1): S45-S52.
[56]
Vardeny O. The sweet spot: heart failure prevention with SGLT2 inhibitors[J]. Am J Med, 2020, 133(2): 182-185.
[57]
Hu Y, Bai Z, Tang Y, et al. Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a pharmacovigilance study with data from the U. S. FDA Adverse Event Reporting System[J]. J Diabetes Res, 2020, 2020: 3695101.
[58]
Handelsman Y, Henry RR, Bloomgarden ZT, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis[J]. Endocr Pract, 2016, 22(6): 753-762.
[59]
Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD[J]. Eur Heart J, 2020, 41(2): 255-323.
[60]
American Diabetes Association. Cardiovascular disease and risk management: standards of medical care in diabetes-2021[J]. Diabetes Care, 2021, 44(Suppl 1): S125-S150.
[61]
Gao Y, Peterson E, Pagidipati N. Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits[J]. Am Heart J, 2020, 224: 47-53.
[62]
Hamid A, Vaduganathan M, Oshunbade AA, et al. Antihyperglycemic therapies with expansions of US Food and Drug Administration Indications to reduce cardiovascular events: prescribing patterns within an academic medical center[J]. J Cardiovasc Pharmacol, 2020, 76(3): 313-320.
[63]
O'meara E, Mcdonald M, Chan M, et al. CCS/CHFS Heart Failure Guidelines: clinical trial update on functional mitral regurgitation, SGLT2 inhibitors, arni in HFpEF, and tafamidis in amyloidosis[J]. Can J Cardiol, 2020, 36(2): 159-169.
[64]
Maddox TM, Januzzi JL Jr, Allen LA, et al. 2021 Update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American college of cardiology solution set oversight committee[J]. J Am Coll Cardiol, 2021, 77(6): 772-810.
2022年第43卷第6期
19
7
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2022.06.001
  • 接收时间:2021-12-01
  • 首发时间:2026-11-19
  • 出版时间:2022-06-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2021-12-01
  • 修回日期:2022-04-12
基金
上海市“医苑新星”青年医学人才培养资助计划(青年医学人才类——临床药师项目)
作者信息
    1.陆军特色医学中心药剂科,重庆 400042
    2.海军军医大学第二附属医院药剂科,上海 200433

通讯作者:

陶霞,教授,博士,主任药师,研究方向:临床药学与心血管药理学。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2022.06.001
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏